GENE ONLINE|News &
Opinion
Blog

2022 psychedelics
Shifting From Counterculture to Clinical Applications, The Problems Psychedelics Face Getting to Market
2022-07-22
Refining Psychedelics into Medicine – An Interview with Doug Drysdale, CEO of Cybin
2022-04-19
The Renaissance of Psychedelics Research: An Interview with the CEO of MindMed, Rob Barrow
2022-04-12
WSJ Health Forum 2022: Psychedelics Set to Take Center Stage in Mental Wellness
2022-03-24
Low Doses of LSD as a Potential Treatment for Anxiety in the Future?
2022-03-22
History on Depression Therapy: the Past and the Psychedelic Future
2022-03-21
Cure or Poison? New Ventures Go IPO Continuously As “Psychedelics” Enter the Mental Health Market
2022-03-09
From Forbidden Drugs to Psychotropic Cures: A “Psychedelic Boom” Breaks New Ground in Treating Mental Illnesses
2022-03-08
LATEST
Pfizer’s RSV Vaccine Gets FDA Approval for Use in Older Adults
2023-05-31
Brazil’s Evolving ESG Landscape from the Amazon to Atlantic Forest
2023-05-31
Should People Looking to Lose Weight Skip Sugar Substitutes?
2023-05-30
Advancing Next-Generation Cancer Metabolic Therapy by Targeting Critical Amino Acid Metabolic Pathways: An Interview with Brian A. Van Tine, MD, PhD
2023-05-26
Rona Therapeutics, Keymed Biosciences Team Up To Develop siRNA Drugs For Kidney Disease
2023-05-25
CDC Calls an End to J&J’s COVID-19 Vaccine in the U.S.
2023-05-25
A Close Look at the Evolution of ESG in Biopharma
2023-05-22
Scroll to Top